Cervical Cancer

The Food and Drug Administration approved Tivdak for metastatic cervical cancer that progressed on or after chemotherapy.

Research has found simple hysterectomy to not be inferior to radical hysterectomy among patients with low-risk cervical cancer.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.

The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer.

Linda Ryan, a patient advocate, details her treatment journey with cervical cancer and discusses resources available to patients.

After introducing the panel, Claire Friedman, MD, provides a brief overview of the screening process, prognosis, and treatment of cervical cancer.

Sexual activity and vaginal dilation could make follow-up examinations more “tolerable” and “pain free” for survivors of cervical cancer after radiotherapy.

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Survivors of cervical cancer who engage in sexual activity or vaginal dilation after radiation could be at lower risk for developing long term side effects.

Tivdak improved overall survival in patients with recurrent or metastatic cervical cancer, compared with chemotherapy alone.

HPV vaccination rates and public knowledge about the connection between the virus and certain cancer types are below what they should be, research found.

This analysis of the KEYNOTE-826 trial focused on health-related quality of life in patients with persistent, recurrent or metastatic cervical cancer.

Efficacy with robotic surgery in early-stage cervical cancer is currently being studied, to hopefully offer patients an option with better recovery compared to open surgery.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.

Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.

AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.

With newer treatments like Keytruda (pembrolizumab) approved for patients with cervical cancer, a younger patient population may be concerned about experiencing side effects that interrupt their lives — but if they occur, clinicians will be ready with a plan for management, says an expert from the Uniformed Services University of the Health Sciences.

One woman explains how after experiencing irregular bleeding, she found out she had cervical cancer and her life changed immediately.

The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.

The antibody drug conjugate could provide patients with symptomatic relief, along with manageable side effects.

Tivdak is a targeted therapy that showed promising results for patients with pretreated metastatic or recurrent cervical cancer.

Transvaginal ultrasonography may inaccurately measure uterine lining in Black women, highlighting the potential to assess its use on a case-by-case basis.

Pap tests should be replaced by more accurate HPV DNA tests, the organization says.

From a dance tribute performed by Kevin Boseman, late actor Chadwick Boseman’s brother to the humorous coloring book a woman created during treatment for cancer, here’s what’s happening in the cancer landscape this week.

Treatment with chemotherapy following the standard chemoradiation treatment failed to improve multiple survival outcomes in women with locally advanced cervical cancer.

Almost 20 years of data indicate that the incidence of HPV-related cervical cancer is noticeably declining, however other cancers related to the virus continue, and are expected, to increase.

Treatment with tisotumab vedotin, a novel antibody-drug conjugate, in women with recurrent or metastatic cervical cancer, led to an objective response rate of 24% with a manageable safety profile.